Separate terms with OR to return results that match either term.
 
Clear All
10,000 Matching Results — Export these results
Click column titles once to sort ascending, and twice to sort descending.
Show Entries
NDC-11 (Package) NDC-9 (Product) Generic Name Brand Name Strength SEER*Rx Category Major Class Minor Class Administration Route Package Effective Date Package Discontinuation Date (Ascending) Status
00046-1100-52 00046-1100 Estrogens, Conjugated Premarin 0.3 mg/1 Hormonal Therapy Estrogen Oral Nov. 11, 2019 In Use
00046-1100-81 00046-1100 Estrogens, Conjugated Premarin 0.3 mg/1 Hormonal Therapy Estrogen Oral Jan. 1, 2006 In Use
00046-1100-91 00046-1100 Estrogens, Conjugated Premarin 0.3 mg/1 Hormonal Therapy Estrogen Oral Jan. 1, 2006 In Use
00046-1102-52 00046-1102 Estrogens, Conjugated Premarin 0.625 mg/1 Hormonal Therapy Estrogen Oral Feb. 10, 2020 In Use
00046-1102-81 00046-1102 Estrogens, Conjugated Premarin 0.625 mg/1 Hormonal Therapy Estrogen Oral Jan. 1, 2006 In Use
00046-1102-91 00046-1102 Estrogens, Conjugated Premarin 0.625 mg/1 Hormonal Therapy Estrogen Oral Jan. 1, 2006 In Use
00046-1104-81 00046-1104 Estrogens, Conjugated Premarin 1.25 mg/1 Hormonal Therapy Estrogen Oral Sept. 1, 2004 In Use
00046-1104-91 00046-1104 Estrogens, Conjugated Premarin 1.25 mg/1 Hormonal Therapy Estrogen Oral Sept. 1, 2004 In Use
00069-1305-10 00069-1305 epoetin alfa-epbx RETACRIT 2000.0 [iU]/mL Ancillary Therapy Erythropoiesis-Stimulating Agent Intravenous, Subcutaneous June 18, 2018 In Use
00069-1307-10 00069-1307 epoetin alfa-epbx RETACRIT 4000.0 [iU]/mL Ancillary Therapy Erythropoiesis-Stimulating Agent Intravenous, Subcutaneous June 18, 2018 In Use
00069-1308-10 00069-1308 epoetin alfa-epbx RETACRIT 10000.0 [iU]/mL Ancillary Therapy Erythropoiesis-Stimulating Agent Intravenous, Subcutaneous June 18, 2018 In Use
00069-1309-04 00069-1309 epoetin alfa-epbx RETACRIT 40000.0 [iU]/mL Ancillary Therapy Erythropoiesis-Stimulating Agent Intravenous, Subcutaneous June 18, 2018 In Use
00069-1309-10 00069-1309 epoetin alfa-epbx RETACRIT 40000.0 [iU]/mL Ancillary Therapy Erythropoiesis-Stimulating Agent Intravenous, Subcutaneous June 18, 2018 In Use
00069-1306-10 00069-1306 epoetin alfa-epbx RETACRIT 3000.0 [iU]/mL Ancillary Therapy Erythropoiesis-Stimulating Agent Intravenous, Subcutaneous June 18, 2018 In Use
00069-1318-04 00069-1318 epoetin alfa-epbx RETACRIT 10000.0 [iU]/mL Ancillary Therapy Erythropoiesis-Stimulating Agent Intravenous, Subcutaneous Dec. 1, 2020 In Use
00069-1318-10 00069-1318 epoetin alfa-epbx RETACRIT 10000.0 [iU]/mL Ancillary Therapy Erythropoiesis-Stimulating Agent Intravenous, Subcutaneous Nov. 9, 2020 In Use
00074-7269-50 00074-7269 Cyclosporine Gengraf 100.0 mg/mL Ancillary Therapy Immunomodulator Calcineurin Inhibitor Oral May 25, 2010 In Use
00078-0109-01 00078-0109 Cyclosporine Sandimmune 50.0 mg/mL Ancillary Therapy Immunomodulator Calcineurin Inhibitor Intravenous Nov. 14, 1983 In Use
00078-0109-61 00078-0109 Cyclosporine Sandimmune 50.0 mg/mL Ancillary Therapy Immunomodulator Calcineurin Inhibitor Intravenous Aug. 10, 2012 In Use
00078-0180-01 00078-0180 Octreotide Acetate Sandostatin 50.0 ug/mL Hormonal Therapy Somatostatin Analog Intravenous, Subcutaneous Oct. 21, 1988 In Use
00078-0180-61 00078-0180 Octreotide Acetate Sandostatin 50.0 ug/mL Hormonal Therapy Somatostatin Analog Intravenous, Subcutaneous Aug. 13, 2012 In Use
00078-0181-01 00078-0181 Octreotide Acetate Sandostatin 100.0 ug/mL Hormonal Therapy Somatostatin Analog Intravenous, Subcutaneous Oct. 21, 1988 In Use
00078-0181-61 00078-0181 Octreotide Acetate Sandostatin 100.0 ug/mL Hormonal Therapy Somatostatin Analog Intravenous, Subcutaneous Aug. 13, 2012 In Use
00078-0182-01 00078-0182 Octreotide Acetate Sandostatin 500.0 ug/mL Hormonal Therapy Somatostatin Analog Intravenous, Subcutaneous Oct. 21, 1988 In Use
00078-0182-61 00078-0182 Octreotide Acetate Sandostatin 500.0 ug/mL Hormonal Therapy Somatostatin Analog Intravenous, Subcutaneous Aug. 13, 2012 In Use
00078-0240-15 00078-0240 Cyclosporine Sandimmune 25.0 mg/1 Ancillary Therapy Immunomodulator Calcineurin Inhibitor Oral March 2, 1990 In Use
00078-0240-61 00078-0240 Cyclosporine Sandimmune 25.0 mg/1 Ancillary Therapy Immunomodulator Calcineurin Inhibitor Oral March 22, 2010 In Use
00078-0241-15 00078-0241 Cyclosporine Sandimmune 100.0 mg/1 Ancillary Therapy Immunomodulator Calcineurin Inhibitor Oral March 2, 1990 In Use
00078-0241-61 00078-0241 Cyclosporine Sandimmune 100.0 mg/1 Ancillary Therapy Immunomodulator Calcineurin Inhibitor Oral March 22, 2010 In Use
00078-0246-15 00078-0246 Cyclosporine NeOral 25.0 mg/1 Ancillary Therapy Immunomodulator Calcineurin Inhibitor Oral July 14, 1995 In Use
00078-0246-61 00078-0246 Cyclosporine NeOral 25.0 mg/1 Ancillary Therapy Immunomodulator Calcineurin Inhibitor Oral Aug. 13, 2012 In Use
00078-0248-15 00078-0248 cyclosporine NeOral 100.0 mg/1 Ancillary Therapy Immunomodulator Calcineurin Inhibitor Oral July 14, 1995 In Use
00078-0248-61 00078-0248 cyclosporine NeOral 100.0 mg/1 Ancillary Therapy Immunomodulator Calcineurin Inhibitor Oral Aug. 13, 2012 In Use
00078-0566-51 00078-0566 Everolimus Afinitor 5.0 mg/1 Chemotherapy Enzyme Inhibitor mTOR Oral March 31, 2009 In Use
00078-0566-61 00078-0566 Everolimus Afinitor 5.0 mg/1 Chemotherapy Enzyme Inhibitor mTOR Oral March 22, 2010 In Use
00078-0567-51 00078-0567 Everolimus Afinitor 10.0 mg/1 Chemotherapy Enzyme Inhibitor mTOR Oral March 31, 2009 In Use
00078-0567-61 00078-0567 Everolimus Afinitor 10.0 mg/1 Chemotherapy Enzyme Inhibitor mTOR Oral March 22, 2010 In Use
00078-0594-51 00078-0594 Everolimus Afinitor 2.5 mg/1 Chemotherapy Enzyme Inhibitor mTOR Oral July 9, 2010 In Use
00078-0594-61 00078-0594 Everolimus Afinitor 2.5 mg/1 Chemotherapy Enzyme Inhibitor mTOR Oral July 9, 2010 In Use
00078-0620-51 00078-0620 Everolimus Afinitor 7.5 mg/1 Chemotherapy Enzyme Inhibitor mTOR Oral July 29, 2011 In Use
00078-0620-61 00078-0620 Everolimus Afinitor 7.5 mg/1 Chemotherapy Enzyme Inhibitor mTOR Oral July 29, 2011 In Use
00078-0626-51 00078-0626 Everolimus Afinitor 2.0 mg/1 Chemotherapy Enzyme Inhibitor mTOR Oral Aug. 29, 2012 In Use
00078-0626-61 00078-0626 Everolimus Afinitor 2.0 mg/1 Chemotherapy Enzyme Inhibitor mTOR Oral Aug. 29, 2012 In Use
00078-0627-51 00078-0627 Everolimus Afinitor 3.0 mg/1 Chemotherapy Enzyme Inhibitor mTOR Oral Aug. 29, 2012 In Use
00078-0627-61 00078-0627 Everolimus Afinitor 3.0 mg/1 Chemotherapy Enzyme Inhibitor mTOR Oral Aug. 29, 2012 In Use
00078-0628-51 00078-0628 Everolimus Afinitor 5.0 mg/1 Chemotherapy Enzyme Inhibitor mTOR Oral Aug. 29, 2012 In Use
00078-0628-61 00078-0628 Everolimus Afinitor 5.0 mg/1 Chemotherapy Enzyme Inhibitor mTOR Oral Aug. 29, 2012 In Use
00078-0669-13 00078-0669 Ofatumumab Arzerra 20.0 mg/mL Immunotherapy Monoclonal Antibody CD20 Intravenous Feb. 1, 2016 In Use
00078-0669-61 00078-0669 Ofatumumab Arzerra 20.0 mg/mL Immunotherapy Monoclonal Antibody CD20 Intravenous Feb. 1, 2016 In Use
00078-0698-02 00078-0698 RYDAPT Rydapt 25.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor FLT3 Oral April 28, 2017 In Use
00078-0698-19 00078-0698 RYDAPT Rydapt 25.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor FLT3 Oral April 28, 2017 In Use
00078-0698-51 00078-0698 RYDAPT Rydapt 25.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor FLT3 Oral April 28, 2017 In Use
00078-0698-99 00078-0698 RYDAPT Rydapt 25.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor FLT3 Oral April 28, 2017 In Use
00078-0709-56 00078-0709 Capmatinib TABRECTA 150.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor MET Oral May 6, 2020 In Use
00078-0709-94 00078-0709 Capmatinib TABRECTA 150.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor MET Oral May 6, 2020 In Use
00078-0716-56 00078-0716 Capmatinib TABRECTA 200.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor MET Oral May 6, 2020 In Use
00078-0716-94 00078-0716 Capmatinib TABRECTA 200.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor MET Oral May 6, 2020 In Use
00078-0867-14 00078-0867 Ribociclib Kisqali 200.0 mg/1, 200.0 mg/1 Chemotherapy Cyclin Dependent Kinase Inhibitor CDK 4/6 Oral March 13, 2017 In Use
00078-0867-42 00078-0867 Ribociclib Kisqali 200.0 mg/1, 200.0 mg/1 Chemotherapy Cyclin Dependent Kinase Inhibitor CDK 4/6 Oral March 13, 2017 In Use
00078-0874-21 00078-0874 Ribociclib Kisqali 200.0 mg/1, 200.0 mg/1 Chemotherapy Cyclin Dependent Kinase Inhibitor CDK 4/6 Oral March 13, 2017 In Use
00078-0874-63 00078-0874 Ribociclib Kisqali 200.0 mg/1, 200.0 mg/1 Chemotherapy Cyclin Dependent Kinase Inhibitor CDK 4/6 Oral March 13, 2017 In Use
00085-1366-03 00085-1366 Temozolomide Temodar 100.0 mg/1 Chemotherapy Alkylating Agent Tetrazine Oral Aug. 11, 1999 In Use
00085-1366-04 00085-1366 Temozolomide Temodar 100.0 mg/1 Chemotherapy Alkylating Agent Tetrazine Oral Aug. 11, 1999 In Use
00085-1366-05 00085-1366 Temozolomide Temodar 100.0 mg/1 Chemotherapy Alkylating Agent Tetrazine Oral Nov. 2, 2012 In Use
00085-1417-02 00085-1417 Temozolomide Temodar 250.0 mg/1 Chemotherapy Alkylating Agent Tetrazine Oral Aug. 11, 1999 In Use
00085-1417-03 00085-1417 Temozolomide Temodar 250.0 mg/1 Chemotherapy Alkylating Agent Tetrazine Oral Nov. 2, 2012 In Use
00085-1425-03 00085-1425 Temozolomide Temodar 140.0 mg/1 Chemotherapy Alkylating Agent Tetrazine Oral Aug. 11, 1999 In Use
00085-1425-04 00085-1425 Temozolomide Temodar 140.0 mg/1 Chemotherapy Alkylating Agent Tetrazine Oral Aug. 11, 1999 In Use
00085-1425-05 00085-1425 Temozolomide Temodar 140.0 mg/1 Chemotherapy Alkylating Agent Tetrazine Oral Nov. 2, 2012 In Use
00085-1430-03 00085-1430 Temozolomide Temodar 180.0 mg/1 Chemotherapy Alkylating Agent Tetrazine Oral Aug. 11, 1999 In Use
00085-1430-04 00085-1430 Temozolomide Temodar 180.0 mg/1 Chemotherapy Alkylating Agent Tetrazine Oral Aug. 11, 1999 In Use
00085-1430-05 00085-1430 Temozolomide Temodar 180.0 mg/1 Chemotherapy Alkylating Agent Tetrazine Oral Nov. 2, 2012 In Use
00085-1519-03 00085-1519 Temozolomide Temodar 20.0 mg/1 Chemotherapy Alkylating Agent Tetrazine Oral Aug. 11, 1999 In Use
00085-1519-04 00085-1519 Temozolomide Temodar 20.0 mg/1 Chemotherapy Alkylating Agent Tetrazine Oral Aug. 11, 1999 In Use
00085-1519-05 00085-1519 Temozolomide Temodar 20.0 mg/1 Chemotherapy Alkylating Agent Tetrazine Oral Nov. 2, 2012 In Use
00085-3004-03 00085-3004 Temozolomide Temodar 5.0 mg/1 Chemotherapy Alkylating Agent Tetrazine Oral Aug. 11, 1999 In Use
00085-3004-04 00085-3004 Temozolomide Temodar 5.0 mg/1 Chemotherapy Alkylating Agent Tetrazine Oral Aug. 11, 1999 In Use
00085-3004-05 00085-3004 Temozolomide Temodar 5.0 mg/1 Chemotherapy Alkylating Agent Tetrazine Oral Nov. 2, 2012 In Use
00143-9744-01 00143-9744 Granisetron Hydrochloride Granisetron Hydrochloride 1.0 mg/mL Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Intravenous Dec. 23, 2009 In Use
00143-9744-10 00143-9744 Granisetron Hydrochloride Granisetron Hydrochloride 1.0 mg/mL Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Intravenous Dec. 23, 2009 In Use
00143-9745-01 00143-9745 Granisetron Hydrochloride Granisetron Hydrochloride 1.0 mg/mL Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Intravenous Dec. 23, 2009 In Use
00143-9745-05 00143-9745 Granisetron Hydrochloride Granisetron Hydrochloride 1.0 mg/mL Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Intravenous Dec. 23, 2009 In Use
00143-9745-10 00143-9745 Granisetron Hydrochloride Granisetron Hydrochloride 1.0 mg/mL Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Intravenous Dec. 23, 2009 In Use
00143-9890-01 00143-9890 Ondansetron Ondansetron 2.0 mg/mL Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Intramuscular, Intravenous Dec. 26, 2006 In Use
00143-9890-10 00143-9890 Ondansetron Ondansetron 2.0 mg/mL Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Intramuscular, Intravenous Dec. 26, 2006 In Use
00143-9891-01 00143-9891 Ondansetron Ondansetron 2.0 mg/mL Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Intramuscular, Intravenous July 15, 2014 In Use
00143-9891-25 00143-9891 Ondansetron Ondansetron 2.0 mg/mL Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Intramuscular, Intravenous Dec. 26, 2006 In Use
00310-0668-12 00310-0668 Olaparib Lynparza 100.0 mg/1 Chemotherapy Enzyme Inhibitor PARP Oral Aug. 17, 2017 In Use
00310-0668-60 00310-0668 Olaparib Lynparza 100.0 mg/1 Chemotherapy Enzyme Inhibitor PARP Oral Aug. 17, 2017 In Use
00310-0668-95 00310-0668 Olaparib Lynparza 100.0 mg/1 Chemotherapy Enzyme Inhibitor PARP Oral Sept. 1, 2022 In Use
00310-0720-10 00310-0720 Fulvestrant Faslodex 50.0 mg/mL Hormonal Therapy Estrogen Receptor Antagonist Intramuscular Nov. 1, 2010 In Use
00378-1936-01 00378-1936 Lenalidomide Lenalidomide 5.0 mg/1 Immunotherapy Immunomodulator Thalidomide Analog Oral Sept. 6, 2022 In Use
00378-1936-28 00378-1936 Lenalidomide Lenalidomide 5.0 mg/1 Immunotherapy Immunomodulator Thalidomide Analog Oral Sept. 6, 2022 In Use
00378-1937-01 00378-1937 Lenalidomide Lenalidomide 10.0 mg/1 Immunotherapy Immunomodulator Thalidomide Analog Oral Sept. 6, 2022 In Use
00378-1937-28 00378-1937 Lenalidomide Lenalidomide 10.0 mg/1 Immunotherapy Immunomodulator Thalidomide Analog Oral Sept. 6, 2022 In Use
00378-1940-01 00378-1940 Lenalidomide Lenalidomide 25.0 mg/1 Immunotherapy Immunomodulator Thalidomide Analog Oral Sept. 6, 2022 In Use
00378-1940-21 00378-1940 Lenalidomide Lenalidomide 25.0 mg/1 Immunotherapy Immunomodulator Thalidomide Analog Oral Sept. 6, 2022 In Use
00378-1941-01 00378-1941 Lenalidomide Lenalidomide 15.0 mg/1 Immunotherapy Immunomodulator Thalidomide Analog Oral Sept. 6, 2022 In Use
00378-1941-21 00378-1941 Lenalidomide Lenalidomide 15.0 mg/1 Immunotherapy Immunomodulator Thalidomide Analog Oral Sept. 6, 2022 In Use
00378-6611-85 00378-6611 Isotretinoin Amnesteem 10.0 mg/1 Hormonal Therapy Immunomodulator Retinoic Acid Derivative Oral Sept. 11, 2015 In Use

Found 10,000 results in 11 milliseconds — Export these results